News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

Former Genentech (DNA) Veteran Joins Immusol, Inc. To Advance Therapeutic Development Efforts

10/19/2005 5:09:43 PM

SAN DIEGO, Jan. 20 /PRNewswire/ -- Immusol announced today that Nicholas F. Paoni, Ph.D. has joined its senior management team as Vice President of Therapeutics. Dr. Paoni will lead development efforts for the company's protein therapeutic and small molecule-based drug programs.

Dr. Paoni recently served as Research Professor in the Department of Chemistry and Biochemistry at the University of Notre Dame where he was also appointed to two research centers, the W.M. Keck Center for Transgene Research as Associate Director, and the Walther Cancer Research Center where he also served as a member of the Executive Committee. Prior to Notre Dame, Dr. Paoni served nearly 20 years at Genentech, Inc. as a Scientist in the Recovery Process Research and Development Department and as a Senior Scientist in the Cardiovascular Research Department. While at Genentech, Dr. Paoni contributed to research and development of two commercial products, the thrombolytic tissue-type plasminogen activators Activase(R) and TNKase(TM), and led a project team for heart failure research.

"It is with great pleasure that we welcome Nick to our team," remarked Dr. Flossie Wong-Staal, Immusol Chief Scientific Officer and Executive Vice President of Research. "His successful and extensive experience in the drug development process will be a tremendous asset to our organization."

Dr. Paoni received a Bachelor of Science degree in biochemistry from the University of California, Davis and a doctorate in chemistry with an emphasis in biochemistry from the University of Notre Dame.

About Immusol:

Immusol is a privately-held San Diego based biopharmaceutical company engaged in discovery and development of novel therapies to treat human diseases. Immusol uses an integrated biology approach, starting with a proprietary drug discovery technology to discover therapeutic proteins and targets in the areas of cancer, viral infection, ophthalmology and neurodegenerative and metabolic diseases. Based on these discoveries, Immusol develops protein and small molecule based therapies alone or in collaboration with drug development partners. Immusol has several lead drug candidates in various stages of clinical and pre-clinical development.


CONTACT: Andrea Lynn, Marketing Manager of Immusol, +1-858-824-1100

Read at

comments powered by Disqus